Excited to have this forward-looking trial available for our patients! PREDICT-RD (TBCRC-071) seeks to improve outcomes in high risk TNBC by combining ctDNA monitoring and early intervention with a TROP2-ADC. @UNC_Lineberger @TheTBCRC @NateraGenetics @BCRFcure #bcsm #tnbc
Can ctDNA help us detect molecular residual disease and guide personalized treatment in patients with high-risk TNBC?View quoted post on X
Our @TheTBCRC PREDICT-RD trial is investigating MRD-guided treatment with datopotamab deruxtecan (Dato-DXd) in patients with persistent ctDNA after neoadjuvant therapy and surgery.
Now open at @UNC_Lineberger and @ONealCancerUAB
Opening soon at @UChicago, @MontefioreNYC @MayoCancerCare & @DukeCancer
Thank you @PRIMR_MED for highlighting our study and helping raise awareness!
🎥 Watch below!
#bcsm